

Special Issue

Head and Neck Cancer: Advanced PET/CT and MRI Imaging with a Focus on Current and Emerging Molecular Theranostics

Message from the Guest Editors

A rapidly developing paradigm in cancer therapy involves the use of highly specific molecularly targeted agents for both PET imaging and targeted radionuclide therapy; this is commonly referred to as theranostics. We first review the current means of imaging squamous cell carcinoma of the head and neck using both anatomical imaging and FDG PET, followed by contemporary treatment options. This provides a perspective of where more specific PET imaging and therapy could potentially play a role in advancing patients' care. We then review the current imaging and therapy used to treat thyroid cancer, followed by how the emerging radiotracers could help. Paragangliomas, rare neuroendocrine tumors of the head and neck, show promising results with targeted somatostatin receptor imaging using DOTATATE. An exciting new class of targeting agents, Fibrinogen Activating Protein inhibitors (FAPI), have shown promising results for imaging squamous cell carcinomas, in addition to many other tumors. Finally, we look at several promising radiotracer ligands under development.

Guest Editors

Prof. Dr. Bennett Chin
Dr. Jorge Oldan
Prof. Dr. Steven P. Rowe

Deadline for manuscript submissions

closed (28 April 2026)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/194887

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)